Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan

Ni, Yen‐Hsuan; Chang, Mei–Hwei; Jan, Chyi-Feng; Chen, Huey‐Ling; Wu, Jiafeng; Chen, Ding‐Shinn

doi:10.1016/j.cgh.2016.04.030

Cited by 76 publications

(66 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we cannot obtain the data directly from this study, one recent research from NI et al. disclosed that 10 of the 12 (83.3%) hepatitis B viral carriers born after neonatal immunization program had a positive maternal status . According to them, HBsAg genotype C pregnant mothers are more likely to be HBeAg positive and more likely to infect their newborn babies.…”

Section: Discussionmentioning

confidence: 78%

Higher disappearance rate of anti‐HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine

Hsu

Chih

Lee

et al. 2017

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 78%

Higher disappearance rate of anti‐HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine

Hsu

Chih

Lee

et al. 2017

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…101,102 The most recent data (from 2016) show that HBsAg positivity in people aged up to 30 years has decreased from more than 11% in 1984 to 0·5% in 2014 (appendix p 5). 103 For those older than 30 years, HBsAg positivity was still about 7% in 2016. 103 Despite active control programmes, the decline of the hepatitis B burden was slow, as shown in a populationbased survey with longitudinal follow-up.…”

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

“…103 For those older than 30 years, HBsAg positivity was still about 7% in 2016. 103 Despite active control programmes, the decline of the hepatitis B burden was slow, as shown in a populationbased survey with longitudinal follow-up. 104 An outreach community-based screening in 164 302 adults in Taiwan from 1996 to 2005 estimated that the total number of HBsAg carriers was about 3 million, indicating the carrier loads of hepatitis B had remained substantial.…”

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Sarin

Kumar

Eslam

et al. 2020

The Lancet Gastroenterology & Hepatology

Self Cite

365

303

View full text Add to dashboard Cite

The Asia-Pacific region is home to more than half of the global population and accounted for 62·6% of global deaths due to liver diseases in 2015. 54·3% of global deaths due to cirrhosis, 72·7% of global deaths due to hepatocellular carcinoma, and more than two-thirds of the global burden of acute viral hepatitis occurred in this region in 2015. Chronic hepatitis B virus (HBV) infection caused more than half of the deaths due to cirrhosis in the region, followed by alcohol consumption (20·8%), non-alcoholic fatty liver disease (NAFLD; 12·1%), and chronic infection with hepatitis C virus (HCV; 15·7%). In 2015, HBV accounted for about half the cases of hepatocellular carcinoma in the region. Preventive strategies for viral hepatitis-related liver disease include increasing access to clean drinking water and sanitation. HBV vaccination programmes for neonates have been implemented by all countries, although birthdose coverage is extremely suboptimal in some. Availability of screening tests for blood and tissue, donor recall policies, and harm reduction strategies are in their initial stages in most countries. Many governments have put HBV and HCV drugs on their essential medicines lists and the availability of generic versions of these drugs has reduced costs. Efforts to eliminate viral hepatitis as a public health threat, together with the rapid increase in per-capita alcohol consumption in countries and the epidemic of obesity, are expected to change the spectrum of liver diseases in the Asia-Pacific region in the near future. The increasing burden of alcohol-related liver diseases can be contained through government policies to limit consumption and promote less harmful patterns of alcohol use, which are in place in some countries but need to be enforced more strictly. Steps are needed to control obesity and NAFLD, including policies to promote healthy lifestyles and regulate the food industry. Inadequate infrastructure and insufficient health-care personnel trained in liver diseases are issues that also need to be addressed in the Asia-Pacific region. The policy response of most governments to liver diseases has thus far been inadequate and poorly funded. There must be a renewed focus on prevention, early detection, timely referral, and research into the best means to introduce and improve health interventions to reduce the burden of liver diseases in the Asia-Pacific region. 168 www.thelancet.com/gastrohep Vol 5 February 2020The Lancet Gastroenterology & Hepatology Commission accounted for 108 276 (8·2%) of the total liver-related deaths in the region in 2015, compared with 929 (1·2%) of 72 437 in the USA and 4032 (0·3%) of 197 179 in Europe. Deaths in the Asia-Pacific region represented three-quarters of the global total number of deaths due to acute viral hepatitis. In 2015, the region accounted for three-quarters of the global total number of deaths related to acute HBV, almost two-thirds of those due to acute hepatitis A infection, and almost 80% of those due to acute hepatitis E infection. Of all deaths du...

show abstract

“…After 10 years of follow‐up, 85% of the vaccinated cohorts remained anti‐HBs positive . Other studies have reported vaccination coverage of nearly 90%; the prevalence of positive HBsAg is as low as 0.5% in children . Compared with the unvaccinated population, the vaccinated population has a significantly lower risk of progressive illnesses from viral hepatitis infections .…”

Section: Discussionmentioning

confidence: 97%

Mortality trends of liver diseases from 1981 to 2016 and the projection to 2035 in Taiwan: An age‐period‐cohort analysis

Lee

2019

Liver International

View full text Add to dashboard Cite

Background Projections on liver diseases mortality can provide a basis for evaluating the World Health Organization's “25 by 25” goal and can help healthcare systems design appropriate control strategies. This study evaluated whether the 25 by 25 goal can be achieved in Taiwan and discussed possible future control strategies. Methods Age‐period‐cohort models are used to estimate the mortality trends of liver diseases from 1981 to 2016 and project these trends to 2035. Results For chronic liver disease and cirrhosis among men, the age‐adjusted mortality rate decreased from 1981 to 1991, increased until 1999, and subsequently decreased again until 2016. For women, the age‐adjusted mortality rate exhibited an increasing but up‐and‐down trend from 1981 to 1998 and a decreasing trend to 2016. For liver cancer among men, the age‐adjusted mortality rate exhibited an increasing trend from 1981 to 2002 and a decreasing trend to 2016. For women, the age‐adjusted mortality rate exhibited an increasing trend from 1981 to 2003 and a decreasing trend to 2016. The age‐adjusted mortality rates of chronic liver disease, cirrhosis and liver cancer for both sexes are projected to decrease by more than 30% from 2016 to 2025 and by more than 55% from 2016 to 2035. Conclusion These results indicated that the 25 by 25 goal can be achieved for liver diseases mortality in Taiwan. In addition to viral hepatitis, the following risk factors may become the major causes of liver diseases in Taiwan in the future: alcohol and tobacco use, diabetes and obesity.

show abstract

Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan

Cited by 76 publications

References 38 publications

Higher disappearance rate of anti‐HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine

Higher disappearance rate of anti‐HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Mortality trends of liver diseases from 1981 to 2016 and the projection to 2035 in Taiwan: An age‐period‐cohort analysis

Contact Info

Product

Resources

About